Regeneron Pharmaceuticals, Inc. - REGN
About Gravity Analytica
Recent News
- 09.24.2025 - Bernstein Insights
- 09.17.2025 - Results from Phase 2 COURAGE Trial Demonstrating Potential to Improve Quality of GLP-1 receptor agonist-induced Weight Loss by Preserving Lean Mass, Presented at EASD
- 09.17.2025 - Regeneron Announces Positive Phase 3 Trial in Adults with Ultra-Rare Genetic Disorder Fibrodysplasia Ossificans Progressiva (FOP), Demonstrating that Garetosmab Prevents Greater than 99% of Abnormal Bone Formation
- 09.09.2025 - Libtayo® (cemiplimab) Plus Chemotherapy Results at Five Years Reinforce Significant and Durable Improvements in Survival Outcomes for Advanced Non-small Cell Lung Cancer
- 09.08.2025 - Morgan Stanley 23rd Annual Global Healthcare Conference
- 09.08.2025 - Regeneron Advances Allergy Pipeline with Two Positive Phase 3 Trials Evaluating First-in-Class Antibody-Blockers of Cat and Birch Allergies
- 09.04.2025 - Regeneron Announces Updated Presentation Time for Upcoming Investor Conference
- 09.04.2025 - 2025 Wells Fargo Healthcare Conference
- 09.03.2025 - Cantor Global Healthcare Conference 2025
- 08.26.2025 - Regeneron Announces Positive Results from Phase 3 Trial in Generalized Myasthenia Gravis